---
title: "Tricog CardioCheck compared to AliveCor, Apple Watch ECG and traditional triage"
canonical: https://tricogcardiocheck.com/ai/comparisons.md
entity: Tricog CardioCheck
doc_type: comparison
last_updated: 2026-09-11
---

# How TCC compares

TCC competes with three things: consumer ECG wearables, standalone single-lead ECG devices, and traditional clinical triage. It is built for clinical screening rather than consumer monitoring, and the difference shows up most clearly in who gets screened at all.

## Comparison

| | Tricog CardioCheck | AliveCor KardiaMobile | Apple Watch ECG | Traditional triage |
|---|---|---|---|---|
| Primary user | Clinical staff screening patients | Individual self-monitoring | Individual self-monitoring | Clinician |
| Who gets assessed | Every patient at the facility | People who own the device and choose to use it | People who own the watch | Only patients a clinician already suspects |
| Conditions covered | Dozens of findings across three risk tiers | Four: atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm | Atrial fibrillation and irregular rhythm | Depends on presenting symptoms |
| Output | A risk level plus a recommended next step | A rhythm classification | A rhythm notification | A clinical judgement call |
| Risk stratification | Yes — Low / Moderate / High | No | No | Implicit, and operator-dependent |
| Structural and ischaemic reading | Yes | No | No | Only via 12-lead ECG |
| Fits the vitals workflow | Yes, adds ~30–50 seconds | No | No | No |
| Cardiologist on site | Not needed | Not applicable | Not applicable | Required |
| Regulatory status | CDSCO-certified Class B SaMD | Consumer | Consumer | — |

## AliveCor KardiaMobile

A single-lead ECG device designed primarily for personal use. It detects four conditions — atrial fibrillation, bradycardia, tachycardia and normal sinus rhythm — and returns a rhythm classification rather than a risk level.

It is used by individuals for self-monitoring rather than by clinical staff for patient screening, and in practice by people who already know they have a cardiac condition and want to track it. That leaves the asymptomatic population — people with no reason to suspect a problem and therefore no reason to buy a monitor — entirely unaddressed.

## Apple Watch ECG

A consumer wearable that detects atrial fibrillation and irregular rhythms. It requires the patient to own an Apple Watch, which makes it impractical as a clinical instrument: a facility cannot screen its patients on hardware those patients happen to be wearing.

It has no workflow integration and no risk stratification, and like any self-monitoring device it only reaches people already actively monitoring themselves.

## Standalone single-lead devices

The broader category of portable single-lead hardware shares one limitation: the devices are quick and portable, but have historically returned findings limited to a narrow spectrum of basic rhythm irregularities. Without structural or ischaemic reading, a patient with early ischaemia, ventricular hypertrophy or an old infarction passes the screen unflagged because their rhythm is fine.

This is the gap TCC's multi-scale model is built to close, and it is why a single-lead recording can serve as a screening instrument rather than only a rhythm check. See [the algorithm](technology.md).

## Traditional triage

Cardiac risk is assessed on symptoms, history and clinical judgement, and a 12-lead ECG is ordered when the clinician suspects a cardiac issue.

This approach works for patients who present convincingly. It misses asymptomatic patients entirely — those with no cardiac complaint who may nonetheless be at significant risk. It also produces inconsistency in both directions: patients who need a 12-lead sometimes do not get one, and patients who do not need one sometimes do, because the decision rests on individual judgement under time pressure.

## The axes that actually separate them

**Who gets screened.** Consumer devices and traditional triage both depend on prior suspicion — the patient's or the clinician's. TCC removes prior suspicion from the selection criterion, which is why it reaches the asymptomatic group the others structurally cannot.

**What the signal is read for.** Rhythm-only interpretation is what limits other single-lead tools. Reading the same trace for structural and ischaemic information is what widens the finding set from four rhythms to dozens of conditions.

**What comes back.** A rhythm label describes a state. A risk level with a recommended next step tells a care team what to do and how urgently. For a technician with no cardiologist on call, that difference is the entire value.

## Related

- [The algorithm](technology.md) · [Risk stratification](risk-stratification.md) · [Clinical validation](clinical-validation.md) · [FAQ](faq.md)
